CA2568897C - Saturated and unsaturated 3-pyridyl-benzocycloalkylmethyl-amines for use in the treatment of pains, depressions and anxiety states - Google Patents
Saturated and unsaturated 3-pyridyl-benzocycloalkylmethyl-amines for use in the treatment of pains, depressions and anxiety states Download PDFInfo
- Publication number
- CA2568897C CA2568897C CA2568897A CA2568897A CA2568897C CA 2568897 C CA2568897 C CA 2568897C CA 2568897 A CA2568897 A CA 2568897A CA 2568897 A CA2568897 A CA 2568897A CA 2568897 C CA2568897 C CA 2568897C
- Authority
- CA
- Canada
- Prior art keywords
- pyridin
- corresponding hydrochloride
- dimethylaminomethyl
- ylmethyl
- amine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000002193 Pain Diseases 0.000 title claims abstract description 36
- 208000019901 Anxiety disease Diseases 0.000 title claims abstract description 25
- 230000036407 pain Effects 0.000 title claims abstract description 20
- 229920006395 saturated elastomer Polymers 0.000 title claims description 21
- 208000020401 Depressive disease Diseases 0.000 title description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 88
- 239000003814 drug Substances 0.000 claims abstract description 22
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 11
- 208000032841 Bulimia Diseases 0.000 claims abstract description 11
- 206010006550 Bulimia nervosa Diseases 0.000 claims abstract description 11
- 208000030814 Eating disease Diseases 0.000 claims abstract description 11
- 208000019454 Feeding and Eating disease Diseases 0.000 claims abstract description 11
- 208000026139 Memory disease Diseases 0.000 claims abstract description 11
- 208000003251 Pruritus Diseases 0.000 claims abstract description 11
- 208000028017 Psychotic disease Diseases 0.000 claims abstract description 11
- 208000000323 Tourette Syndrome Diseases 0.000 claims abstract description 11
- 208000016620 Tourette disease Diseases 0.000 claims abstract description 11
- 206010046543 Urinary incontinence Diseases 0.000 claims abstract description 11
- 208000010877 cognitive disease Diseases 0.000 claims abstract description 11
- 235000014632 disordered eating Nutrition 0.000 claims abstract description 11
- 208000002271 trichotillomania Diseases 0.000 claims abstract description 11
- 229940079593 drug Drugs 0.000 claims abstract description 10
- 208000013403 hyperactivity Diseases 0.000 claims abstract description 9
- 208000004296 neuralgia Diseases 0.000 claims abstract description 9
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims abstract 7
- 206010013663 drug dependence Diseases 0.000 claims abstract 7
- 208000011117 substance-related disease Diseases 0.000 claims abstract 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 182
- 239000000203 mixture Substances 0.000 claims description 41
- 238000006243 chemical reaction Methods 0.000 claims description 30
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 25
- -1 dimethyl-(5-pyridin-3-yl-8,9-dihydro-7H-benzocyclohepten-6-ylmethyl) amine Chemical class 0.000 claims description 23
- 150000003839 salts Chemical class 0.000 claims description 23
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 21
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 19
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 17
- 229910052740 iodine Inorganic materials 0.000 claims description 17
- 229910052794 bromium Inorganic materials 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 15
- 229910052801 chlorine Inorganic materials 0.000 claims description 14
- 239000012458 free base Substances 0.000 claims description 14
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 13
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 11
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- 150000001412 amines Chemical class 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 9
- QRKAPEZZSALFQR-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-5-methoxy-1-pyridin-3-yl-3,4-dihydro-2h-naphthalen-1-ol Chemical compound COC1=CC=CC2=C1CCC(CN(C)C)C2(O)C1=CC=CN=C1 QRKAPEZZSALFQR-UHFFFAOYSA-N 0.000 claims description 8
- 229910052731 fluorine Inorganic materials 0.000 claims description 8
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims description 8
- KEAOSKLDFWJIGP-UHFFFAOYSA-N 6-[(dimethylamino)methyl]-5-pyridin-3-yl-7,8-dihydronaphthalen-1-ol Chemical compound C12=CC=CC(O)=C2CCC(CN(C)C)=C1C1=CC=CN=C1 KEAOSKLDFWJIGP-UHFFFAOYSA-N 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- 239000003446 ligand Substances 0.000 claims description 7
- CYHKDODPXAVVJY-UHFFFAOYSA-N 1-(5-methoxy-1-pyridin-3-yl-3,4-dihydronaphthalen-2-yl)-n,n-dimethylmethanamine Chemical compound CN(C)CC=1CCC=2C(OC)=CC=CC=2C=1C1=CC=CN=C1 CYHKDODPXAVVJY-UHFFFAOYSA-N 0.000 claims description 6
- CJZGNRDVLLHEER-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-pyridin-3-yl-3h-inden-5-ol Chemical compound C12=CC=C(O)C=C2CC(CN(C)C)=C1C1=CC=CN=C1 CJZGNRDVLLHEER-UHFFFAOYSA-N 0.000 claims description 6
- JRQUDCPZCIGPEF-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-6-methoxy-1-pyridin-3-yl-2,3-dihydroinden-1-ol Chemical compound C12=CC(OC)=CC=C2CC(CN(C)C)C1(O)C1=CC=CN=C1 JRQUDCPZCIGPEF-UHFFFAOYSA-N 0.000 claims description 6
- GDMQXYMWMGHHKE-UHFFFAOYSA-N 3-[(dimethylamino)methyl]-4-pyridin-3-yl-2,3-dihydrochromen-4-ol Chemical compound CN(C)CC1COC2=CC=CC=C2C1(O)C1=CC=CN=C1 GDMQXYMWMGHHKE-UHFFFAOYSA-N 0.000 claims description 6
- 239000002585 base Substances 0.000 claims description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 6
- YGCWTLJXPQFPEQ-UHFFFAOYSA-N n,n-dimethyl-1-(3-pyridin-3-yl-1h-inden-2-yl)methanamine Chemical compound C12=CC=CC=C2CC(CN(C)C)=C1C1=CC=CN=C1 YGCWTLJXPQFPEQ-UHFFFAOYSA-N 0.000 claims description 6
- JKUVGEXRZZWOFY-UHFFFAOYSA-N 1-(6-fluoro-3-pyridin-3-yl-1h-inden-2-yl)-n,n-dimethylmethanamine Chemical compound C12=CC=C(F)C=C2CC(CN(C)C)=C1C1=CC=CN=C1 JKUVGEXRZZWOFY-UHFFFAOYSA-N 0.000 claims description 5
- GQPGBYGEQXBPQQ-UHFFFAOYSA-N 1-(6-methoxy-3-pyridin-3-yl-1h-inden-2-yl)-n,n-dimethylmethanamine Chemical compound CN(C)CC=1CC2=CC(OC)=CC=C2C=1C1=CC=CN=C1 GQPGBYGEQXBPQQ-UHFFFAOYSA-N 0.000 claims description 5
- AYIMCOMVIZKFTL-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-pyridin-3-yl-2,3-dihydroinden-1-ol Chemical compound CN(C)CC1CC2=CC=CC=C2C1(O)C1=CC=CN=C1 AYIMCOMVIZKFTL-UHFFFAOYSA-N 0.000 claims description 5
- YEENLRKTQJLHGC-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-5-fluoro-1-pyridin-3-yl-2,3-dihydroinden-1-ol Chemical compound CN(C)CC1CC2=CC(F)=CC=C2C1(O)C1=CC=CN=C1 YEENLRKTQJLHGC-UHFFFAOYSA-N 0.000 claims description 5
- AHCCCKGSLZERRE-UHFFFAOYSA-N 4-[(dimethylamino)methyl]-5-pyridin-3-yl-3,4-dihydro-2h-1-benzoxepin-5-ol Chemical compound CN(C)CC1CCOC2=CC=CC=C2C1(O)C1=CC=CN=C1 AHCCCKGSLZERRE-UHFFFAOYSA-N 0.000 claims description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 229910052744 lithium Inorganic materials 0.000 claims description 5
- VQEYEIUTACZWBP-UHFFFAOYSA-N n,n-dimethyl-1-[3-pyridin-3-yl-6-(trifluoromethoxy)-1h-inden-2-yl]methanamine Chemical compound C12=CC=C(OC(F)(F)F)C=C2CC(CN(C)C)=C1C1=CC=CN=C1 VQEYEIUTACZWBP-UHFFFAOYSA-N 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 238000006467 substitution reaction Methods 0.000 claims description 5
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 claims description 5
- PRPULZAHTDWDFW-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-pyridin-3-yl-5-(trifluoromethoxy)-2,3-dihydroinden-1-ol Chemical compound CN(C)CC1CC2=CC(OC(F)(F)F)=CC=C2C1(O)C1=CC=CN=C1 PRPULZAHTDWDFW-UHFFFAOYSA-N 0.000 claims description 4
- HCYZQCDUOXFBGY-UHFFFAOYSA-N 3-[(dimethylamino)methyl]-4-pyridin-3-yl-2,3-dihydrothiochromen-4-ol Chemical compound CN(C)CC1CSC2=CC=CC=C2C1(O)C1=CC=CN=C1 HCYZQCDUOXFBGY-UHFFFAOYSA-N 0.000 claims description 4
- AZFNLAWLWJOLDL-UHFFFAOYSA-N 6-[(dimethylamino)methyl]-5-pyridin-3-yl-6,7,8,9-tetrahydrobenzo[7]annulen-5-ol Chemical compound CN(C)CC1CCCC2=CC=CC=C2C1(O)C1=CC=CN=C1 AZFNLAWLWJOLDL-UHFFFAOYSA-N 0.000 claims description 4
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 4
- 229910003204 NH2 Inorganic materials 0.000 claims description 4
- 230000006870 function Effects 0.000 claims description 4
- 238000005984 hydrogenation reaction Methods 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- LAHZKUNEQKCMJZ-UHFFFAOYSA-N n,n-dimethyl-1-(5-pyridin-3-yl-8,9-dihydro-7h-benzo[7]annulen-6-yl)methanamine Chemical compound C12=CC=CC=C2CCCC(CN(C)C)=C1C1=CC=CN=C1 LAHZKUNEQKCMJZ-UHFFFAOYSA-N 0.000 claims description 4
- 125000006239 protecting group Chemical group 0.000 claims description 4
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 claims description 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- VSNLINZDYNIUSB-UHFFFAOYSA-N 1-(5-methoxy-3-pyridin-3-yl-1h-inden-2-yl)-n,n-dimethylmethanamine Chemical compound C12=CC(OC)=CC=C2CC(CN(C)C)=C1C1=CC=CN=C1 VSNLINZDYNIUSB-UHFFFAOYSA-N 0.000 claims description 3
- PWFIDZRWWJSWEM-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-pyridin-3-yl-3,4-dihydro-2h-naphthalen-1-ol Chemical compound CN(C)CC1CCC2=CC=CC=C2C1(O)C1=CC=CN=C1 PWFIDZRWWJSWEM-UHFFFAOYSA-N 0.000 claims description 3
- INBQRBCPBDIRFT-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-pyridin-3-yl-5-(trifluoromethyl)-2,3-dihydroinden-1-ol Chemical compound CN(C)CC1CC2=CC(C(F)(F)F)=CC=C2C1(O)C1=CC=CN=C1 INBQRBCPBDIRFT-UHFFFAOYSA-N 0.000 claims description 3
- HSQDHZQNMRYXIH-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-5-methoxy-1-pyridin-3-yl-2,3-dihydroinden-1-ol Chemical compound C=1C(OC)=CC=C2C=1CC(CN(C)C)C2(O)C1=CC=CN=C1 HSQDHZQNMRYXIH-UHFFFAOYSA-N 0.000 claims description 3
- AVJUYOMQAYCMCY-UHFFFAOYSA-N 4-[(dimethylamino)methyl]-5-pyridin-3-yl-3,4-dihydro-2h-1-benzothiepin-5-ol Chemical compound CN(C)CC1CCSC2=CC=CC=C2C1(O)C1=CC=CN=C1 AVJUYOMQAYCMCY-UHFFFAOYSA-N 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- ZIKZSXHMGBOHMR-UHFFFAOYSA-N n,n-dimethyl-1-(1-pyridin-3-yl-1,2,3,4-tetrahydronaphthalen-2-yl)methanamine Chemical compound CN(C)CC1CCC2=CC=CC=C2C1C1=CC=CN=C1 ZIKZSXHMGBOHMR-UHFFFAOYSA-N 0.000 claims description 3
- AAMBJVCFOBUEQZ-UHFFFAOYSA-N n,n-dimethyl-1-(1-pyridin-3-yl-2,3-dihydro-1h-inden-2-yl)methanamine Chemical compound CN(C)CC1CC2=CC=CC=C2C1C1=CC=CN=C1 AAMBJVCFOBUEQZ-UHFFFAOYSA-N 0.000 claims description 3
- QVNAEAOVUDUJDB-UHFFFAOYSA-N n,n-dimethyl-1-(1-pyridin-3-yl-3,4-dihydronaphthalen-2-yl)methanamine Chemical compound C12=CC=CC=C2CCC(CN(C)C)=C1C1=CC=CN=C1 QVNAEAOVUDUJDB-UHFFFAOYSA-N 0.000 claims description 3
- MVFSHUNZGXRRAO-UHFFFAOYSA-N n,n-dimethyl-1-(4-pyridin-3-yl-2h-chromen-3-yl)methanamine Chemical compound C12=CC=CC=C2OCC(CN(C)C)=C1C1=CC=CN=C1 MVFSHUNZGXRRAO-UHFFFAOYSA-N 0.000 claims description 3
- CRILCMHJXQMVLZ-UHFFFAOYSA-N n,n-dimethyl-1-(5-pyridin-3-yl-2,3-dihydro-1-benzoxepin-4-yl)methanamine Chemical compound C12=CC=CC=C2OCCC(CN(C)C)=C1C1=CC=CN=C1 CRILCMHJXQMVLZ-UHFFFAOYSA-N 0.000 claims description 3
- CPRVRYUDZUPTAT-UHFFFAOYSA-N n,n-dimethyl-1-[3-pyridin-3-yl-6-(trifluoromethyl)-1h-inden-2-yl]methanamine Chemical compound C12=CC=C(C(F)(F)F)C=C2CC(CN(C)C)=C1C1=CC=CN=C1 CPRVRYUDZUPTAT-UHFFFAOYSA-N 0.000 claims description 3
- 238000006683 Mannich reaction Methods 0.000 claims description 2
- 229910052796 boron Inorganic materials 0.000 claims description 2
- 238000003776 cleavage reaction Methods 0.000 claims description 2
- 238000006880 cross-coupling reaction Methods 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 150000002366 halogen compounds Chemical class 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- FRWCVGXMJMQFIM-UHFFFAOYSA-N n,n-dimethyl-1-(4-pyridin-3-yl-2h-thiochromen-3-yl)methanamine Chemical compound C12=CC=CC=C2SCC(CN(C)C)=C1C1=CC=CN=C1 FRWCVGXMJMQFIM-UHFFFAOYSA-N 0.000 claims description 2
- PLWLRPYOGMIRHN-UHFFFAOYSA-N n,n-dimethyl-1-(5-pyridin-3-yl-2,3-dihydro-1-benzothiepin-4-yl)methanamine Chemical compound C12=CC=CC=C2SCCC(CN(C)C)=C1C1=CC=CN=C1 PLWLRPYOGMIRHN-UHFFFAOYSA-N 0.000 claims description 2
- 150000002902 organometallic compounds Chemical class 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 150000002989 phenols Chemical class 0.000 claims description 2
- JKANAVGODYYCQF-UHFFFAOYSA-N prop-2-yn-1-amine Chemical class NCC#C JKANAVGODYYCQF-UHFFFAOYSA-N 0.000 claims description 2
- 230000007017 scission Effects 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052718 tin Inorganic materials 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 claims 3
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims 2
- 238000006555 catalytic reaction Methods 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- TVDSBUOJIPERQY-UHFFFAOYSA-N prop-2-yn-1-ol Chemical compound OCC#C TVDSBUOJIPERQY-UHFFFAOYSA-N 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 230000007704 transition Effects 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 104
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 63
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 53
- 239000000243 solution Substances 0.000 description 41
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 32
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 32
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- 238000001816 cooling Methods 0.000 description 21
- 238000003756 stirring Methods 0.000 description 20
- 230000036506 anxiety Effects 0.000 description 16
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 16
- 235000019341 magnesium sulphate Nutrition 0.000 description 16
- 239000012071 phase Substances 0.000 description 16
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 15
- 230000005764 inhibitory process Effects 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 13
- 239000012074 organic phase Substances 0.000 description 13
- 230000008569 process Effects 0.000 description 13
- 208000000094 Chronic Pain Diseases 0.000 description 12
- 206010026749 Mania Diseases 0.000 description 12
- 239000000741 silica gel Substances 0.000 description 12
- 229910002027 silica gel Inorganic materials 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 11
- 239000012043 crude product Substances 0.000 description 11
- 230000007717 exclusion Effects 0.000 description 11
- 229960002748 norepinephrine Drugs 0.000 description 11
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 208000020925 Bipolar disease Diseases 0.000 description 9
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 229940127240 opiate Drugs 0.000 description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 239000008346 aqueous phase Substances 0.000 description 8
- 125000003118 aryl group Chemical group 0.000 description 8
- 230000006399 behavior Effects 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 8
- 150000001721 carbon Chemical group 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 8
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 7
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 7
- 235000011114 ammonium hydroxide Nutrition 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 125000000623 heterocyclic group Chemical group 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- NYPYPOZNGOXYSU-UHFFFAOYSA-N 3-bromopyridine Chemical compound BrC1=CC=CN=C1 NYPYPOZNGOXYSU-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 206010021030 Hypomania Diseases 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- 230000003040 nociceptive effect Effects 0.000 description 6
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 5
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 5
- 125000002877 alkyl aryl group Chemical group 0.000 description 5
- 230000000407 monoamine reuptake Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 238000004809 thin layer chromatography Methods 0.000 description 5
- WSZXXKMDHROGHF-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-5-methoxy-1-pyridin-3-yl-2,3-dihydroinden-1-ol;hydrochloride Chemical compound Cl.C=1C(OC)=CC=C2C=1CC(CN(C)C)C2(O)C1=CC=CN=C1 WSZXXKMDHROGHF-UHFFFAOYSA-N 0.000 description 4
- 206010012335 Dependence Diseases 0.000 description 4
- 208000001640 Fibromyalgia Diseases 0.000 description 4
- 208000019695 Migraine disease Diseases 0.000 description 4
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 4
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 4
- 208000005298 acute pain Diseases 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 125000001072 heteroaryl group Chemical group 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 206010027599 migraine Diseases 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- FBPFRVCEQMLXSS-UHFFFAOYSA-N n,n-dimethyl-1-(3-pyridin-3-yl-1h-inden-2-yl)methanamine;hydrochloride Chemical compound Cl.C12=CC=CC=C2CC(CN(C)C)=C1C1=CC=CN=C1 FBPFRVCEQMLXSS-UHFFFAOYSA-N 0.000 description 4
- 229910052763 palladium Inorganic materials 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 208000017520 skin disease Diseases 0.000 description 4
- 229960004688 venlafaxine Drugs 0.000 description 4
- TXIAGRUGTPQZPY-UHFFFAOYSA-N 1-(6-fluoro-3-pyridin-3-yl-1h-inden-2-yl)-n,n-dimethylmethanamine;hydrochloride Chemical compound Cl.C12=CC=C(F)C=C2CC(CN(C)C)=C1C1=CC=CN=C1 TXIAGRUGTPQZPY-UHFFFAOYSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- VHMJVWWIOOIBDW-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-5-methoxy-1-pyridin-3-yl-3,4-dihydro-2h-naphthalen-1-ol;hydrochloride Chemical compound Cl.COC1=CC=CC2=C1CCC(CN(C)C)C2(O)C1=CC=CN=C1 VHMJVWWIOOIBDW-UHFFFAOYSA-N 0.000 description 3
- 208000017194 Affective disease Diseases 0.000 description 3
- 125000005865 C2-C10alkynyl group Chemical group 0.000 description 3
- 206010065390 Inflammatory pain Diseases 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 206010033664 Panic attack Diseases 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 208000028683 bipolar I disease Diseases 0.000 description 3
- 208000025307 bipolar depression Diseases 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 239000012876 carrier material Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- QNXSIUBBGPHDDE-UHFFFAOYSA-N indan-1-one Chemical compound C1=CC=C2C(=O)CCC2=C1 QNXSIUBBGPHDDE-UHFFFAOYSA-N 0.000 description 3
- 208000024714 major depressive disease Diseases 0.000 description 3
- 201000003995 melancholia Diseases 0.000 description 3
- VGIVLIHKENZQHQ-UHFFFAOYSA-N n,n,n',n'-tetramethylmethanediamine Chemical compound CN(C)CN(C)C VGIVLIHKENZQHQ-UHFFFAOYSA-N 0.000 description 3
- MGMPQPACTGGECP-UHFFFAOYSA-N n,n-dimethyl-1-(5-pyridin-3-yl-8,9-dihydro-7h-benzo[7]annulen-6-yl)methanamine;hydrochloride Chemical compound Cl.C12=CC=CC=C2CCCC(CN(C)C)=C1C1=CC=CN=C1 MGMPQPACTGGECP-UHFFFAOYSA-N 0.000 description 3
- HHTCNUIQRNVYOI-UHFFFAOYSA-N n,n-dimethyl-1-[3-pyridin-3-yl-6-(trifluoromethoxy)-1h-inden-2-yl]methanamine;hydrochloride Chemical compound Cl.C12=CC=C(OC(F)(F)F)C=C2CC(CN(C)C)=C1C1=CC=CN=C1 HHTCNUIQRNVYOI-UHFFFAOYSA-N 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 208000019906 panic disease Diseases 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 229940076279 serotonin Drugs 0.000 description 3
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 3
- JTJFTHMLDCQKKT-UHFFFAOYSA-N 1-(5-methoxy-1-pyridin-3-yl-3,4-dihydronaphthalen-2-yl)-n,n-dimethylmethanamine;hydrochloride Chemical compound Cl.CN(C)CC=1CCC=2C(OC)=CC=CC=2C=1C1=CC=CN=C1 JTJFTHMLDCQKKT-UHFFFAOYSA-N 0.000 description 2
- WKAXJSVKAGQLSQ-UHFFFAOYSA-N 1-(6-methoxy-3-pyridin-3-yl-1h-inden-2-yl)-n,n-dimethylmethanamine;hydrochloride Chemical compound Cl.CN(C)CC=1CC2=CC(OC)=CC=C2C=1C1=CC=CN=C1 WKAXJSVKAGQLSQ-UHFFFAOYSA-N 0.000 description 2
- YZXXYWYUUBCYTK-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-pyridin-3-yl-2,3-dihydroinden-1-ol;hydrochloride Chemical compound Cl.CN(C)CC1CC2=CC=CC=C2C1(O)C1=CC=CN=C1 YZXXYWYUUBCYTK-UHFFFAOYSA-N 0.000 description 2
- ZBOOYBIVSNLAQR-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-pyridin-3-yl-3h-inden-5-ol;hydrochloride Chemical compound Cl.C12=CC=C(O)C=C2CC(CN(C)C)=C1C1=CC=CN=C1 ZBOOYBIVSNLAQR-UHFFFAOYSA-N 0.000 description 2
- RJJAPTUXYIJMRX-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-pyridin-3-yl-5-(trifluoromethoxy)-2,3-dihydroinden-1-ol;hydrochloride Chemical compound Cl.CN(C)CC1CC2=CC(OC(F)(F)F)=CC=C2C1(O)C1=CC=CN=C1 RJJAPTUXYIJMRX-UHFFFAOYSA-N 0.000 description 2
- RTWTVJFXVOXZAI-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-pyridin-3-yl-5-(trifluoromethyl)-2,3-dihydroinden-1-ol;hydrochloride Chemical compound Cl.CN(C)CC1CC2=CC(C(F)(F)F)=CC=C2C1(O)C1=CC=CN=C1 RTWTVJFXVOXZAI-UHFFFAOYSA-N 0.000 description 2
- VCZXLAZXPIQNOK-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-5-fluoro-1-pyridin-3-yl-2,3-dihydroinden-1-ol;hydrochloride Chemical compound Cl.CN(C)CC1CC2=CC(F)=CC=C2C1(O)C1=CC=CN=C1 VCZXLAZXPIQNOK-UHFFFAOYSA-N 0.000 description 2
- SMRWZKSCFZBTGV-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-5-fluoro-2,3-dihydroinden-1-one;hydrochloride Chemical compound Cl.FC1=CC=C2C(=O)C(CN(C)C)CC2=C1 SMRWZKSCFZBTGV-UHFFFAOYSA-N 0.000 description 2
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 description 2
- KNTMEDNZPJADJU-UHFFFAOYSA-N 3,4-dihydro-2h-1-benzoxepin-5-one Chemical compound O=C1CCCOC2=CC=CC=C12 KNTMEDNZPJADJU-UHFFFAOYSA-N 0.000 description 2
- SLOOCJUIRYAQPQ-UHFFFAOYSA-N 4-[(dimethylamino)methyl]-5-pyridin-3-yl-3,4-dihydro-2h-1-benzoxepin-5-ol;hydrochloride Chemical compound Cl.CN(C)CC1CCOC2=CC=CC=C2C1(O)C1=CC=CN=C1 SLOOCJUIRYAQPQ-UHFFFAOYSA-N 0.000 description 2
- AHSXMYSALCGWSP-UHFFFAOYSA-N 5-(trifluoromethyl)-2,3-dihydroinden-1-one Chemical compound FC(F)(F)C1=CC=C2C(=O)CCC2=C1 AHSXMYSALCGWSP-UHFFFAOYSA-N 0.000 description 2
- OABRYVZJJUKADZ-UHFFFAOYSA-N 6-[(dimethylamino)methyl]-5-pyridin-3-yl-6,7,8,9-tetrahydrobenzo[7]annulen-5-ol;hydrochloride Chemical compound Cl.CN(C)CC1CCCC2=CC=CC=C2C1(O)C1=CC=CN=C1 OABRYVZJJUKADZ-UHFFFAOYSA-N 0.000 description 2
- ICKWGXXFMPNALZ-UHFFFAOYSA-N 6-[(dimethylamino)methyl]-5-pyridin-3-yl-7,8-dihydronaphthalen-1-ol;hydrochloride Chemical compound Cl.C12=CC=CC(O)=C2CCC(CN(C)C)=C1C1=CC=CN=C1 ICKWGXXFMPNALZ-UHFFFAOYSA-N 0.000 description 2
- RREANTFLPGEWEN-MBLPBCRHSA-N 7-[4-[[(3z)-3-[4-amino-5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidin-2-yl]imino-5-fluoro-2-oxoindol-1-yl]methyl]piperazin-1-yl]-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(\N=C/3C4=CC(F)=CC=C4N(CN4CCN(CC4)C=4C(=CC=5C(=O)C(C(O)=O)=CN(C=5C=4)C4CC4)F)C\3=O)=NC=2)N)=C1 RREANTFLPGEWEN-MBLPBCRHSA-N 0.000 description 2
- 208000028048 Accommodation disease Diseases 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 101001043818 Mus musculus Interleukin-31 receptor subunit alpha Proteins 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 2
- 206010038678 Respiratory depression Diseases 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 206010040108 Serotonin syndrome Diseases 0.000 description 2
- 206010041250 Social phobia Diseases 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 239000012346 acetyl chloride Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- 230000017858 demethylation Effects 0.000 description 2
- 238000010520 demethylation reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000003001 depressive effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical compound [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- FJJHDKFYUCZYRS-UHFFFAOYSA-N n,n-dimethyl-1-(1-pyridin-3-yl-2,3-dihydro-1h-inden-2-yl)methanamine;hydrochloride Chemical compound Cl.CN(C)CC1CC2=CC=CC=C2C1C1=CC=CN=C1 FJJHDKFYUCZYRS-UHFFFAOYSA-N 0.000 description 2
- 229960004127 naloxone Drugs 0.000 description 2
- 208000021722 neuropathic pain Diseases 0.000 description 2
- BKIMMITUMNQMOS-UHFFFAOYSA-N nonane Chemical compound CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 2
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 2
- 230000000966 norepinephrine reuptake Effects 0.000 description 2
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 208000019899 phobic disease Diseases 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 208000028173 post-traumatic stress disease Diseases 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 2
- ZNSIZMQNQCNRBW-UHFFFAOYSA-N sevelamer Chemical compound NCC=C.ClCC1CO1 ZNSIZMQNQCNRBW-UHFFFAOYSA-N 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- KSBWHDDGWSYETA-SNAWJCMRSA-N (E)-3-(trifluoromethyl)cinnamic acid Chemical compound OC(=O)\C=C\C1=CC=CC(C(F)(F)F)=C1 KSBWHDDGWSYETA-SNAWJCMRSA-N 0.000 description 1
- CMTIHEOOVZATEB-UHFFFAOYSA-N 1-n,1-n,1-n',1-n'-tetramethylethane-1,1-diamine Chemical compound CN(C)C(C)N(C)C CMTIHEOOVZATEB-UHFFFAOYSA-N 0.000 description 1
- VELHUGWCSGRWTQ-UHFFFAOYSA-N 2-(dimethylamino)-2-methyl-1-pyridin-3-yl-5-(trifluoromethoxy)-3h-inden-1-ol Chemical compound CN(C)C1(C)CC2=CC(OC(F)(F)F)=CC=C2C1(O)C1=CC=CN=C1 VELHUGWCSGRWTQ-UHFFFAOYSA-N 0.000 description 1
- GTEAMIIAZMVCSG-UHFFFAOYSA-N 2-(dimethylamino)-2-methyl-1-pyridin-3-yl-5-(trifluoromethoxy)-3h-inden-1-ol;hydrochloride Chemical compound Cl.CN(C)C1(C)CC2=CC(OC(F)(F)F)=CC=C2C1(O)C1=CC=CN=C1 GTEAMIIAZMVCSG-UHFFFAOYSA-N 0.000 description 1
- FKFBLEBNTNLODY-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-pyridin-3-yl-5-(trifluoromethoxy)-2,3-dihydroinden-1-ol 5-(trifluoromethoxy)-2,3-dihydroinden-1-one hydrochloride Chemical compound FC(OC=1C=C2CCC(C2=CC1)=O)(F)F.Cl.CN(C)CC1C(C2=CC=C(C=C2C1)OC(F)(F)F)(O)C=1C=NC=CC1 FKFBLEBNTNLODY-UHFFFAOYSA-N 0.000 description 1
- UEUVQLNDXGDBLK-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-5-(trifluoromethoxy)-2,3-dihydroinden-1-one Chemical compound FC(F)(F)OC1=CC=C2C(=O)C(CN(C)C)CC2=C1 UEUVQLNDXGDBLK-UHFFFAOYSA-N 0.000 description 1
- LDCHJHHRNWNKAY-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-5-(trifluoromethoxy)-2,3-dihydroinden-1-one;hydrochloride Chemical compound Cl.FC(F)(F)OC1=CC=C2C(=O)C(CN(C)C)CC2=C1 LDCHJHHRNWNKAY-UHFFFAOYSA-N 0.000 description 1
- QHNYYAVQWSEQLN-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-5-fluoro-2,3-dihydroinden-1-one Chemical compound FC1=CC=C2C(=O)C(CN(C)C)CC2=C1 QHNYYAVQWSEQLN-UHFFFAOYSA-N 0.000 description 1
- AIGPTOVAWSXKTH-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-5-methoxy-2,3-dihydroinden-1-one Chemical compound COC1=CC=C2C(=O)C(CN(C)C)CC2=C1 AIGPTOVAWSXKTH-UHFFFAOYSA-N 0.000 description 1
- LTYHOOSIBPZOEQ-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-5-methoxy-3,4-dihydro-2h-naphthalen-1-one Chemical compound O=C1C(CN(C)C)CCC2=C1C=CC=C2OC LTYHOOSIBPZOEQ-UHFFFAOYSA-N 0.000 description 1
- YQLFBLALPPKCKU-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-5-methoxy-3,4-dihydro-2h-naphthalen-1-one;hydrochloride Chemical compound Cl.O=C1C(CN(C)C)CCC2=C1C=CC=C2OC YQLFBLALPPKCKU-UHFFFAOYSA-N 0.000 description 1
- TVSPPYGAFOVROT-UHFFFAOYSA-N 2-phenoxybutanoic acid Chemical compound CCC(C(O)=O)OC1=CC=CC=C1 TVSPPYGAFOVROT-UHFFFAOYSA-N 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- WGEVFUNNEITJFQ-UHFFFAOYSA-N 3-[3-(trifluoromethoxy)phenyl]propanoic acid Chemical compound OC(=O)CCC1=CC=CC(OC(F)(F)F)=C1 WGEVFUNNEITJFQ-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- UEGSXBYJSNTXTE-UHFFFAOYSA-N 4-[(dimethylamino)methyl]-5-pyridin-3-yl-3,4-dihydro-2h-1-benzothiepin-5-ol;hydrochloride Chemical compound Cl.CN(C)CC1CCSC2=CC=CC=C2C1(O)C1=CC=CN=C1 UEGSXBYJSNTXTE-UHFFFAOYSA-N 0.000 description 1
- DJGOAKVCWWDUHQ-UHFFFAOYSA-N 5-(trifluoromethoxy)-2,3-dihydroinden-1-one Chemical compound FC(F)(F)OC1=CC=C2C(=O)CCC2=C1 DJGOAKVCWWDUHQ-UHFFFAOYSA-N 0.000 description 1
- WVPPBVAMKNQXJA-UHFFFAOYSA-N 5-fluoro-2,3-dihydroinden-1-one Chemical compound FC1=CC=C2C(=O)CCC2=C1 WVPPBVAMKNQXJA-UHFFFAOYSA-N 0.000 description 1
- BRCPWISABURVIH-UHFFFAOYSA-N 5-methoxy-3,4-dihydro-2h-naphthalen-1-one Chemical compound O=C1CCCC2=C1C=CC=C2OC BRCPWISABURVIH-UHFFFAOYSA-N 0.000 description 1
- KXZUEKMRAUIUJL-UHFFFAOYSA-N 6-[(dimethylamino)methyl]-6,7,8,9-tetrahydrobenzo[7]annulen-5-one Chemical compound O=C1C(CN(C)C)CCCC2=CC=CC=C21 KXZUEKMRAUIUJL-UHFFFAOYSA-N 0.000 description 1
- RHHGHWBHOQXKNZ-UHFFFAOYSA-N 7-(trifluoromethyl)-2,3-dihydroinden-1-one Chemical compound FC(F)(F)C1=CC=CC2=C1C(=O)CC2 RHHGHWBHOQXKNZ-UHFFFAOYSA-N 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- 208000008811 Agoraphobia Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 206010034912 Phobia Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010045171 Tumour pain Diseases 0.000 description 1
- 108010046516 Wheat Germ Agglutinins Proteins 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003502 anti-nociceptive effect Effects 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- AZWXAPCAJCYGIA-UHFFFAOYSA-N bis(2-methylpropyl)alumane Chemical compound CC(C)C[AlH]CC(C)C AZWXAPCAJCYGIA-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N diisobutylaluminium hydride Substances CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 1
- GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008517 inhibition of serotonin uptake Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- RGPDIGOSVORSAK-STHHAXOLSA-N naloxone hydrochloride Chemical compound Cl.O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C RGPDIGOSVORSAK-STHHAXOLSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000005069 octynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003402 opiate agonist Substances 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002900 organolithium compounds Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010517 secondary reaction Methods 0.000 description 1
- 230000020341 sensory perception of pain Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000000697 serotonin reuptake Effects 0.000 description 1
- 230000013275 serotonin uptake Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 201000001716 specific phobia Diseases 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 210000003568 synaptosome Anatomy 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000003797 telogen phase Effects 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- AWIJRPNMLHPLNC-UHFFFAOYSA-N thiocarboxylic acid group Chemical group C(=S)O AWIJRPNMLHPLNC-UHFFFAOYSA-N 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 239000005051 trimethylchlorosilane Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004030099.2 | 2004-06-22 | ||
| DE102004030099A DE102004030099A1 (de) | 2004-06-22 | 2004-06-22 | Gesättigte und ungesättigte 3-Pyridyl-benzocycloalkylmethyl-amine als Serotonin- und/oder Noradrenalin-Reuptake-Hemmer und/oder µ-Opioidrezeptor-Modulatoren |
| PCT/EP2005/006624 WO2005123681A1 (de) | 2004-06-22 | 2005-06-20 | Gesättigte und ungesättigte 3-pyridyl-benzocycloalkylmethyl-amine zur behandlung von schmerzen, depressionen und angstzuständen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2568897A1 CA2568897A1 (en) | 2005-12-29 |
| CA2568897C true CA2568897C (en) | 2012-08-07 |
Family
ID=35106829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2568897A Expired - Fee Related CA2568897C (en) | 2004-06-22 | 2005-06-20 | Saturated and unsaturated 3-pyridyl-benzocycloalkylmethyl-amines for use in the treatment of pains, depressions and anxiety states |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8278338B2 (OSRAM) |
| EP (1) | EP1758860B1 (OSRAM) |
| JP (1) | JP4918486B2 (OSRAM) |
| AT (1) | ATE441632T1 (OSRAM) |
| CA (1) | CA2568897C (OSRAM) |
| CY (1) | CY1109519T1 (OSRAM) |
| DE (2) | DE102004030099A1 (OSRAM) |
| DK (1) | DK1758860T3 (OSRAM) |
| ES (1) | ES2333976T3 (OSRAM) |
| PL (1) | PL1758860T3 (OSRAM) |
| PT (1) | PT1758860E (OSRAM) |
| SI (1) | SI1758860T1 (OSRAM) |
| WO (1) | WO2005123681A1 (OSRAM) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7435837B2 (en) | 2003-10-24 | 2008-10-14 | Wyeth | Dihydrobenzofuranyl alkanamine derivatives and methods for using same |
| AU2006239918A1 (en) | 2005-04-22 | 2006-11-02 | Wyeth | New therapeutic combianations for the treatment or prevention of depression |
| US8053603B2 (en) * | 2006-01-06 | 2011-11-08 | Sunovion Pharmaceuticals Inc. | Tetralone-based monoamine reuptake inhibitors |
| WO2009121872A2 (en) | 2008-04-01 | 2009-10-08 | Abbott Gmbh & Co. Kg | Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy |
| AR075442A1 (es) | 2009-02-16 | 2011-03-30 | Abbott Gmbh & Co Kg | Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia |
| US9051280B2 (en) | 2010-08-13 | 2015-06-09 | AbbVie Deutschland GmbH & Co. KG | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US8877794B2 (en) | 2010-08-13 | 2014-11-04 | Abbott Laboratories | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US8846743B2 (en) | 2010-08-13 | 2014-09-30 | Abbott Laboratories | Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US8883839B2 (en) | 2010-08-13 | 2014-11-11 | Abbott Laboratories | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9045459B2 (en) | 2010-08-13 | 2015-06-02 | AbbVie Deutschland GmbH & Co. KG | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9309200B2 (en) | 2011-05-12 | 2016-04-12 | AbbVie Deutschland GmbH & Co. KG | Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| JP2014521682A (ja) * | 2011-08-05 | 2014-08-28 | アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー | アミノクロマン、アミノチオクロマンおよびアミノ−１，２，３，４−テトラヒドロキノリン誘導体、これらを含有する医薬組成物、ならびに治療におけるこれらの使用 |
| CN104011028A (zh) | 2011-11-18 | 2014-08-27 | 艾伯维德国有限责任两合公司 | N-取代的氨基苯并环庚烯、氨基四氢化萘、氨基茚满和苯烷基胺衍生物、包含所述衍生物的药物组合物及其在治疗中的用途 |
| US9365512B2 (en) | 2012-02-13 | 2016-06-14 | AbbVie Deutschland GmbH & Co. KG | Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9650334B2 (en) | 2013-03-15 | 2017-05-16 | Abbvie Inc. | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9656955B2 (en) | 2013-03-15 | 2017-05-23 | Abbvie Inc. | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9643947B2 (en) | 2013-08-28 | 2017-05-09 | Northwestern University | 7-membered fused heterocycles and methods of their synthesis |
| MX2016004934A (es) | 2013-10-17 | 2016-12-20 | Abbvie Deutschland | Derivados de aminotetralina y aminoindano, composiciones farmaceuticas que los contienen, y su uso en terapia. |
| CN105992764A (zh) | 2013-10-17 | 2016-10-05 | 艾伯维德国有限责任两合公司 | 氨基色满、氨基硫代色满及氨基-1,2,3,4-四氢喹啉衍生物，包含其的药物组合物及其在治疗中的用途 |
| CN104844471B (zh) * | 2015-04-21 | 2017-05-03 | 苏州远智医药科技有限公司 | 一种作为dor受体拮抗剂的化合物 |
| CN109896991B (zh) * | 2017-12-08 | 2020-11-20 | 苏州远智医药科技有限公司 | 一种δ阿片受体拮抗剂及其用途和药物组合物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3444176A (en) * | 1967-04-28 | 1969-05-13 | Mcneilab Inc | Certain 4-diloweralkylamino-lower alkyl - 5 - pyridyl (or phenyl)-2,3-dihydro - 1 - benzothiepins and derivatives thereof |
| US4845221A (en) * | 1988-04-15 | 1989-07-04 | American Home Products Corporation | Serotonergic substituted piperazinyl tetralins |
| CA2095718A1 (en) * | 1990-11-22 | 1992-05-23 | Hans-Rudolf Waespe | Isonicotinic acid derivatives and related spiro compounds with herbicidal action |
| US5668141A (en) * | 1996-04-02 | 1997-09-16 | Abbott Laboratories | Trans-2,6-,3,6-and 4,6-diaza-5,6,6a,7,8,12b-hexahydrobenzo[c]phenanthrene compounds as dopamine agonists |
| DE19805370A1 (de) * | 1997-03-14 | 1998-09-17 | Gruenenthal Gmbh | Substituierte Aminoverbindungen und ihre Verwendung als analgetisch wirksame Substanzen |
| AU4037699A (en) * | 1998-05-08 | 1999-11-29 | Akzo Nobel N.V. | Novel aryl-hydro naphthalenal kanamines |
| TW555757B (en) * | 1998-07-31 | 2003-10-01 | Akzo Nobel Nv | Aminomethylcarboxylic acid derivatives |
| CO5271697A1 (es) * | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona |
| CA2440238C (en) * | 2001-03-16 | 2011-09-13 | Abbott Laboratories | Novel amines as histamine-3 receptor ligands and their therapeutic applications |
| WO2003004485A1 (fr) * | 2001-07-05 | 2003-01-16 | Takeda Chemical Industries, Ltd. | Composes heterocycles a 5 chainons condenses avec un benzo, leur procede de preparation et leur utilisation |
| JP2004149429A (ja) * | 2002-10-29 | 2004-05-27 | Takeda Chem Ind Ltd | インドール化合物およびその用途 |
-
2004
- 2004-06-22 DE DE102004030099A patent/DE102004030099A1/de not_active Withdrawn
-
2005
- 2005-06-20 SI SI200530854T patent/SI1758860T1/sl unknown
- 2005-06-20 DK DK05766092T patent/DK1758860T3/da active
- 2005-06-20 AT AT05766092T patent/ATE441632T1/de active
- 2005-06-20 ES ES05766092T patent/ES2333976T3/es not_active Expired - Lifetime
- 2005-06-20 WO PCT/EP2005/006624 patent/WO2005123681A1/de not_active Ceased
- 2005-06-20 PT PT05766092T patent/PT1758860E/pt unknown
- 2005-06-20 DE DE502005008058T patent/DE502005008058D1/de not_active Expired - Lifetime
- 2005-06-20 EP EP05766092A patent/EP1758860B1/de not_active Expired - Lifetime
- 2005-06-20 PL PL05766092T patent/PL1758860T3/pl unknown
- 2005-06-20 JP JP2007517174A patent/JP4918486B2/ja not_active Expired - Fee Related
- 2005-06-20 CA CA2568897A patent/CA2568897C/en not_active Expired - Fee Related
-
2006
- 2006-12-22 US US11/643,792 patent/US8278338B2/en not_active Expired - Fee Related
-
2009
- 2009-11-30 CY CY20091101251T patent/CY1109519T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1758860A1 (de) | 2007-03-07 |
| CA2568897A1 (en) | 2005-12-29 |
| US8278338B2 (en) | 2012-10-02 |
| JP4918486B2 (ja) | 2012-04-18 |
| EP1758860B1 (de) | 2009-09-02 |
| DE502005008058D1 (de) | 2009-10-15 |
| PL1758860T3 (pl) | 2010-02-26 |
| PT1758860E (pt) | 2009-12-07 |
| ES2333976T3 (es) | 2010-03-03 |
| CY1109519T1 (el) | 2014-08-13 |
| DK1758860T3 (da) | 2010-01-11 |
| DE102004030099A1 (de) | 2006-01-12 |
| SI1758860T1 (sl) | 2010-01-29 |
| JP2008503523A (ja) | 2008-02-07 |
| WO2005123681A1 (de) | 2005-12-29 |
| ATE441632T1 (de) | 2009-09-15 |
| US20070203192A1 (en) | 2007-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2568897C (en) | Saturated and unsaturated 3-pyridyl-benzocycloalkylmethyl-amines for use in the treatment of pains, depressions and anxiety states | |
| EP0170213B1 (en) | Glutarimide antianxiety and antihypertensive agents | |
| US20090137837A1 (en) | Methods of synthesizing cinacalcet and salts thereof | |
| PL204661B1 (pl) | Fenyloetyloaminy i odmiany skondensowanych układów pierścieniowych jako proleki katecholamin, kompozycja farmaceutyczna zawierająca te związki oraz ich zastosowanie | |
| HUE025381T2 (en) | Compounds for the inhibition of SSAO / VAP-1 and their use for the treatment and prevention of diseases | |
| MXPA02001372A (es) | Derivados sustituidos de 2-dialquilaminoalquilbifenilo. | |
| JPS5943956B2 (ja) | 新規なジベンゾピラン類 | |
| KR20070015613A (ko) | 카복사미도 아편유사약물 화합물 | |
| FI94240C (fi) | Menetelmä terapeuttisesti käyttökelpoisten 4-aryyli-4-piperidiinikarbinolien valmistamiseksi | |
| CN101565409A (zh) | 哌嗪或高哌嗪草酰肼类化合物及其制备方法和用途 | |
| US6214882B1 (en) | Benzenesulphonamide derivatives, preparation thereof and therapeutical uses thereof | |
| US4612312A (en) | Glutarimide antianxiety and antihypertensive agents | |
| IL150558A (en) | History of Aminomethyl-Phenyl-Cyclo-Cyclone | |
| PL195667B1 (pl) | Nowe związki cykliczne zawierające łańcuch cyklopropylenowy, sposób ich wytwarzania, kompozycje farmaceutyczne zawierające te związki i ich zastosowanie | |
| JPH05255302A (ja) | 新規なクロマニルオキシアルキルアミン誘導体 | |
| CN101312961B (zh) | 异喹啉与苯并[h]异喹啉衍生物，它们的制备及其作为组胺h3受体拮抗药的治疗用途 | |
| EP1257527B1 (en) | (2s)-aminoindan derivatives, a process for their preparation and their use as selective dopamine d3 ligands | |
| EP1603877B1 (en) | NOVEL AMINOPYRIDINE DERIVATIVES AS mGIuR5 ANTAGONISTS | |
| US5158948A (en) | Tetracyclic spirobenzazepine dopamine antagonists | |
| CY1521A (en) | Substituted 1-pyridyloxy-3-indolylalkylamino-2-propanols,preparation and use thereof | |
| JPH04308557A (ja) | アルキルアミノアルキルアミン−および−エーテル化合物、その製造方法、およびそれを含有する胃腸管の鎮痙用の医薬 | |
| CA2509072C (en) | Saturated and unsaturated heteroarylcycloalkylmethyl-amines as antidepressants | |
| CA2573754C (en) | Substituted amino compounds as 5-ht/na uptake inhibitors | |
| GB2276164A (en) | Aniline and benzanilide derivatives | |
| US5109006A (en) | Certain pharmaceutically active 6H-imidazo[1,2-a]pyridine-5-ones |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20140620 |